Phase II Trial of Low-Dose Methotrexate and Iodine I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Trial Profile

Phase II Trial of Low-Dose Methotrexate and Iodine I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Methotrexate
  • Indications Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jun 2016 Status changed from suspended to discontinued as Bexxar isn't being produced by the manufacturer as of Feb. 2014
    • 03 Oct 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 04 Jun 2013 15 patients were enrolled between August 2011 and October 2012, according to ASCO 2013 abstract.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top